Heart
01 Jan 2013
Perioperative stress response in infants undergoing cardiac surgery: a comparison of three alfentanil dosage regimens
Perioperative stress response in infants undergoing cardiac surgery: a comparison of three alfentanil dosage regimens Official Title Conditions Study Type Study Design Further Details What is the smallest dose of alfentanil that minimises neuro-hormonal stress response in infants undergoing cardiac surgery? 90 infants aged less than 1 year undergoing palliative…
Heart
01 Jan 2013
Predictors of Response to Cardiac Resynchronization Therapy
Predictors of Response to Cardiac Resynchronization Therapy. Official Title Conditions Study Type Study Design Further Details This important study will use echocardiograms to learn how to better predict heart failure patients who will have a positive response to biventricular pacing therapy. As this technology advances, it will be important to…
Heart
01 Jan 2013
(AFast) Atrial Fibrillation Suppression Trial
Suppression of Atrial Fibrillation in Patients without a Bradycardia Indication for Pacing. Official Title Conditions Study Type Study Design Further Details This trial will offer patients, who have atrial fibrillation without bradycardia, the option of a pacemaker to control their irregular heartbeats. For those patients whose irregular rhythms cannot be…
Heart
01 Jan 2013
GUSTO IV-ACS
Glycoprotein IIb/IIIa blockers reduce procedure-related thrombotic complications of percutaneous coronary intervention, and the risk of death and myocardial infarction in patients with acute coronary syndromes. The effect on risk of death and myocardial infarction is particularly apparent in patients undergoing early percutaneous coronary interventions. We did a randomized, mutlicenter trial…
Heart
01 Jan 2013
TARGET
In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal myocardial infarction at 30 days. We assessed whether there are differences in safety or efficacy between two such inhibitors, tirofiban and abciximab. In the…
Heart
01 Jan 2013
TACTICS-TIMI 18
There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST segment elevation. There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for…
Heart
01 Jan 2013
EPISTENT
Coronary stenting with use of heparin, aspirin, and ticlopidine for thromboprophylaxis is performed in more than 500 000 patients per year worldwide. We did a randomised controlled trial to assess the role of platelet glycoprotein-IIb/IIIa blockade for use in elective stenting. Coronary stenting with use of heparin, aspirin, and ticlopidine…
Heart
01 Jan 2013
EPILOG
Blockade of the platelet glycoprotein IIb/IIIa receptor with abciximab (a monoclonal-antibody Fab fragment directed against the receptor) has been shown to diminish ischemic complications among patients undergoing high-risk coronary angioplasty or directional atherectomy but increases bleeding complications. The widespread applicability of this treatment is unknown, particularly in view of the…
Heart
01 Jan 2013
STOPAMI-2
Patients with acute myocardial infarction might benefit from the addition of glycoprotein IIb/IIIa inhibitors to fibrinolytic or mechanical reperfusion strategies. We compared two strategies, stenting and fibrinolysis, both combined with abciximab, in terms of their ability to salvage myocardium in patients with acute myocardial infarction. Patients with acute myocardial infarction…
